Peter C. Richardson

Chief Scientific Officer, MannKind Corporation.

Companies

Keenova Therapeutics plcEVP & Chief Scientific Officer Jan 20, 2023 to now¹
ANTARES PHARMA, INC.EVP, R&D Chief Medical Officer Apr 28, 2021 to May 26, 2022²
MannKind CorporationChief Scientific Officer Dec 14, 2006 to Mar 6, 2012³

Holdings

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

Shares held

ANTARES PHARMA, INC.0 shares⁴May 24, 2022
Keenova Therapeutics plc3,419 shares⁵Jan 1, 2025

As of each latest filing. The line shows shares held over time.

Recent filings

Jan 1, 2025Exercised options 3,419 shares of Keenova Therapeutics plc⁵
Nov 14, 2023Returned to company 75,091 shares of Keenova Therapeutics plc⁶
Feb 2, 2023Granted 75,091 shares of Keenova Therapeutics plc⁷
May 24, 2022Returned to company 14,414 shares at $5.60 of ANTARES PHARMA, INC.⁴
May 24, 2022Returned to company 36,199 shares at $5.60 of ANTARES PHARMA, INC.⁴

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARKeenova Therapeutics plc, EVP & Chief Scientific Officer
2
SEC EDGARANTARES PHARMA, INC., EVP, R&D Chief Medical Officer
3
SEC EDGARMannKind Corporation, Chief Scientific Officer
4
SEC EDGARANTARES PHARMA, INC. shares after the filing of May 24, 2022
5
SEC EDGARKeenova Therapeutics plc shares after the filing of Jan 1, 2025
6
SEC EDGARForm 4 filed Nov 16, 2023
7
SEC EDGARForm 4 filed Feb 3, 2023